Here's the News...

The U.S. Food and Drug Administration approved Genzyme's(GENZ) Lumizyme as a treatment for Pompe disease, a rare genetic disorder, the agency said Tuesday in a statement.

The FDA decision to approve Lumizyme came earlier than expected.

Currently, the only other treatment for Pompe disease available in the U.S. is Myozyme, also made by Genzyme.

In Pompe disease, a gene mutation prevents the body from making an enzyme, necessary for proper muscle functioning. Without the enzyme action, glycogen builds up in the cells and, ultimately, weakens the heart and muscles.